GlassScriptPhysician profile
Kathryn Sullivan
NPI 1831733799
$5,784.37
in general payments reported to CMS, 2019-2025
44 companies · $1,252 in 2025
The $1,252 reported for 2025 was more than what 84% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,864 · 2024: $2,669 · 2025: $1,252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,187 · Education: $597.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,187.48 |
| Education | $596.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $615.96 | 2023-2025 | |
| Janssen Biotech, INC. | $574.70 | 2023-2025 | Darzalex, Rybrevant, Tecvayli |
| Novartis Pharmaceuticals Corporation | $492.44 | 2023-2025 | |
| Seagen INC. | $387.62 | 2023 | Tukysa |
| Astrazeneca Pharmaceuticals LP | $350.23 | 2023-2025 | Enhertu, Tagrisso |
| Rigel Pharmaceuticals, INC. | $292.77 | 2023-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Celgene Corporation | $282.97 | 2023-2025 | Reblozyl, Pomalyst, Opdivo |
| Incyte Corporation | $217.18 | 2023-2025 | Jakafi, Monjuvi, Pemazyre |
| Lilly USA, LLC | $207.79 | 2023-2025 | Jaypirca, Verzenio, Retevmo |
| E.R. Squibb & Sons, L.L.C. | $191.43 | 2023-2025 | Opdivo, Opdualag |
| Pharmaessentia USA Corporation | $163.96 | 2023-2025 | Besremi |
| Bayer Healthcare Pharmaceuticals INC. | $143.89 | 2023-2025 | |
| Pfizer INC. | $133.31 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $131.66 | 2023-2024 | Ninlaro, Alunbrig, Advate |
| Regeneron Healthcare Solutions, INC. | $129.97 | 2023-2025 | Libtayo |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $102.57 | 2024-2025 | Enhertu, Injectafer |
| Coherus Oncology, INC. | $94.77 | 2023-2025 | Udenyca |
| Sobi, INC | $82.23 | 2023-2025 | |
| Genentech USA, INC. | $79.35 | 2023-2025 | Tecentriq, Alecensa, Venclexta |
| Genzyme Corporation | $79.05 | 2023-2024 | |
| Jazz Pharmaceuticals INC. | $78.53 | 2023-2025 | |
| Astellas Pharma US INC | $72.76 | 2024-2025 | Padcev |
| Mirati Therapeutics, INC. | $70.45 | 2024 | Krazati |
| Emd Serono, INC. | $67.49 | 2023-2025 | Bavencio |
| Aveo Pharmaceuticals, INC. | $65.50 | 2024-2025 | |
| Glaxosmithkline, LLC. | $64.08 | 2024 | Ojjaara |
| Karyopharm Therapeutics INC. | $64.04 | 2023-2024 | Xpovio |
| Servier Pharmaceuticals LLC | $56.61 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $55.80 | 2024-2025 | Orgovyx |
| Merck Sharp & Dohme LLC | $51.25 | 2024 | Keytruda, Welireg, Lynparza |
| Stemline Therapeutics INC. | $45.26 | 2023-2024 | Orserdu |
| Progenics Pharmaceuticals, INC. | $41.92 | 2023-2024 | Pylarify |
| Adc Therapeutics America, INC. | $37.80 | 2023-2025 | |
| Myriad Genetic Laboratories, INC. | $32.61 | 2023-2024 | Precisetumor, Myrisk |
| Beigene USA, INC. | $26.33 | 2024 | Brukinsa |
| Alexion Pharmaceuticals, INC. | $26.29 | 2024 | Ultomiris |
| Amgen INC. | $24.88 | 2023 | Kyprolis |
| Eisai INC. | $24.76 | 2023 | |
| Deciphera Pharmaceuticals INC. | $24.30 | 2024 | Qinlock |
| Genmab U.S., INC. | $24.24 | 2024 | Tivdak |
| Gilead Sciences, INC. | $22.13 | 2023 | |
| Exelixis INC. | $18.87 | 2025 | Cabometyx |
| Puma Biotechnology, INC. | $18.72 | 2025 | |
| Agios Pharmaceuticals, INC. | $15.90 | 2025 | Pyrukynd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathryn Sullivan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.